Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals has announced its financial results for the quarter ending December 2024, highlighting a year-on-year increase in net sales and profit before tax. The profit after tax reached a five-quarter high, while earnings per share also improved. However, rising interest costs indicate increased borrowings.

Fredun Pharmaceuticals has recently adjusted its evaluation, highlighting its financial performance in the pharmaceuticals sector. The company reported significant growth in net sales and operating profit for Q2 FY24-25, with notable increases in profit after tax and operational efficiency, despite a challenging year.

Fredun Pharmaceuticals has hit a new 52-week low, with its stock price declining significantly during the trading day. The company has consistently traded below its moving averages, reflecting a persistent downward trend. Over the past year, its stock has decreased notably, contrasting with broader market gains.

Fredun Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has reported positive financial results for the quarter ending September 2024. The company's PAT and net sales have shown significant growth, while its operating profit is at its highest in the last five quarters. However, the rising interest cost is a concern for the company's financials.

Fredun Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, has received a 'Sell' rating from MarketsMOJO on October 14, 2024. This is due to various technical indicators suggesting a bearish trend for the stock. However, the company has shown healthy long-term growth and attractive valuations, making it a stock to watch out for in the future.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its healthy long-term growth, with net sales and operating profit increasing at annual rates of 27.35% and 43.06%, respectively. Despite recent underperformance in the market, the company's attractive valuation and positive financial results make it a stock worth monitoring.

Fredun Pharmaceuticals, a microcap pharmaceutical company, received a 'Sell' rating from MarketsMOJO on September 2nd, 2024 due to its current bearish technical trend. Despite underperforming the market in the past year, the company has shown healthy long-term growth and positive results in the latest quarter. The stock is currently trading at a discount and has potential for future growth, but investors should be aware of potential volatility due to the majority of non-institutional shareholders.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its healthy long-term growth. The company's net sales and operating profit have increased at an annual rate of 27.35% and 43.06%, respectively. Despite a sideways technical trend, the stock has generated a 0.15% return since August 26, 2024. With a ROCE of 15.3 and an attractive valuation, the stock is currently trading at a discount compared to its historical average. However, the stock has underperformed the market with a negative return of -17.74%. The PEG ratio of 0.7 suggests a potential undervaluation, but the presence of non-institutional investors may lead to higher volatility. Overall, Fredun Pharmaceuticals is a hold for now, and investors should monitor its performance in the coming months.

Fredun Pharmaceuticals, a microcap pharmaceutical company, received a 'Sell' rating from MarketsMOJO on 2024-08-19 due to its stock being in a Mildly Bearish range and technical trend deteriorating. Despite underperforming the market in the past year, the company has shown healthy long-term growth and reported positive results in Jun 24. Majority of shareholders are non-institutional investors and profits have risen by 34.5% in the past year, indicating potential for future growth. However, current bearish trend and underperformance in the market should be considered before investing.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its healthy long-term growth, with net sales and operating profit increasing at annual rates of 27.35% and 43.06%, respectively. Despite underperforming in the market, the company's profits have risen by 34.5% and it has an attractive valuation. Majority of shareholders are non-institutional investors.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO on August 6, 2024. This is due to technical indicators showing a mildly bearish trend and underperformance in the market. However, the company has shown strong long-term growth and attractive valuation, making it a potential consideration for investors.

Fredun Pharmaceuticals, a microcap company in the pharmaceutical industry, has reported a positive financial performance for the quarter ending June 2024. With a score of 9 out of 10, compared to 4 in the previous quarter, the company's key areas such as Profit After Tax, Net Sales, and Profit Before Tax have shown significant growth. However, the rising interest cost is a concern. MarketsMOJO has recommended a 'Hold' call for Fredun Pharma's stock.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on 24th July 2024. The upgrade is based on the company's strong long-term growth, technical trend improvement, and attractive valuation. However, the stock has underperformed the market in the last year, which should be considered by potential investors.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO on July 19, 2024 due to its flat results in March 2024 and a decrease of 27.09% in PBT LESS OI(Q). The stock is currently in a Mildly Bearish range and has underperformed the market in the past year, but shows healthy long-term growth and attractive valuation.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on July 1, 2024. The company has shown healthy long-term growth with increasing net sales and operating profit. Technically, the stock is in a Mildly Bullish range with positive indicators. Valuation-wise, it has an attractive ROCE and is trading at a discount. Recent financial results were flat, but the company has outperformed the market in the past year. With a PEG ratio of 0.8, there is potential for future growth. Overall, it is a 'Hold' for investors due to its long-term growth potential and attractive valuation.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to flat results in March 2024 and an increase in interest expenses. The stock is currently in a Mildly Bearish range and has underperformed the market in the past year. However, the company has shown healthy long-term growth and has an attractive valuation.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its healthy long-term growth, with net sales increasing by 29.08% and operating profit at 43.06%. Technical indicators suggest a bullish outlook, while valuation metrics show an attractive ROCE and low enterprise value. However, the company's recent flat results and underperformance in the market should also be considered before investing.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO on May 9, 2024 due to its flat results in March 2024 and a decrease of 27.09% in PBT LESS OI(Q). The stock has also seen a deterioration in its trend and has underperformed the market in the past year. However, the company has shown healthy long-term growth and has an attractive valuation, making it a potential investment opportunity.

Fredun Pharmaceuticals, a microcap pharmaceutical company, has been upgraded to a 'Hold' rating by MarketsMOJO on May 7, 2024. The company has shown healthy long-term growth, with net sales and operating profit increasing at annual rates of 29.24% and 43.06% respectively. The stock is currently in a mildly bullish range and has an attractive valuation, trading at a discount compared to its historical valuations. However, the company's results for December 2023 were flat, which may have contributed to its underperformance in the last year.